Copy
Problems viewing this newsletter? View it in your browser >



January 10, 2012

Dear Advocate,

AVAC is pleased to release the first 2012 issue of Px Wire, our quarterly newsletter covering the latest events in the field of biomedical HIV prevention research, implementation and advocacy. Click to download Px Wire, Vol 5, No 1.

To start off the issue, we identify 10 key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic.

This issue also covers:

  • Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada) indicating that it can be used as HIV prevention in HIV-negative adults.
  • The closure of the 1% tenofovir gel arm of the VOICE trial, which is evaluating oral and topical tenofovir-based PrEP—and a review of other key trials of tenofovir gel.
  • New trials launched this quarter including the French IPERGAY pilot for an efficacy trial of coitally-related oral PrEP using TDF/FTC in MSM.

As always, you’ll find a centerspread with a current map of ongoing prevention trials and a timeline of efficacy trial results worldwide.

Best,
AVAC

 
 

Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 


Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 


Contact Us T: +1 212 796 6423
E: avac@avac.org

W: www.avac.org